| 股號 / 名稱 | 現金及約當現金 | 流動資產 | 總資產 |
| TMO 賽默飛世爾科技 | 129,737,068,683.84 | 745,892,374,458.15 | 3,612,909,205,517.94 |
| ABT 美國雅培 | 162,937,499,646.24 | 782,668,236,447.27 | 3,486,524,103,421.65 |
| LH Labcorp Holdings Inc. | 4,526,751,067.76 | 121,784,926,998.52 | 591,615,718,004.31 |
| DGX 奎斯特診斷 | 19,984,105,560.06 | 90,790,409,285.64 | 540,752,019,300.09 |
| A 安捷倫 | 56,121,497,722.98 | 149,816,944,717.83 | 445,875,403,126.77 |
| BIO Bio-Rad Laboratories, Inc. | 16,504,445,007.27 | 96,424,905,501.86 | 327,279,632,910.12 |
| ILMN Illumina Inc | 33,200,430,962.4 | 90,471,174,372.54 | 212,291,217,211.5 |
| QGEN QIAGEN N.V. | 24,533,203,071.74 | 52,885,317,638.41 | 188,003,888,869.83 |
| NTRA Natera, Inc. | 34,844,554,611.85 | 52,959,475,908.72 | 84,836,582,385.85 |
| TEM Tempus AI, Inc. | 19,141,772,318.35 | 41,208,917,609.88 | 75,528,139,248.73 |
| GH Guardant Health, Inc. | 33,630,408,466.85 | 43,564,041,257.79 | 61,047,100,891.17 |
| VCYT Veracyte, Inc. | 9,561,756,040.66 | 18,348,824,717.71 | 47,449,992,084.48 |
| NEO NeoGenomics, Inc. | 4,646,113,001.77 | 12,178,109,617.96 | 43,168,317,659.51 |
| BLLN BillionToOne, Inc. | 17,514,121,190.42 | 20,794,196,075.54 | 23,294,443,914.94 |
| CSTL Castle Biosciences, Inc. | 1,982,959,586.21 | 10,889,102,885.84 | 17,914,729,082.87 |
| 4169 泰宗 | 896,730,000 | 1,561,198,000 | 2,104,265,000 |
| 6598 ABC-KY | 449,173,000 | 934,031,000 | 1,073,322,000 |
載入數據中...
和癌症診斷相關的產業概念股
癌症診斷概念股相關指標排名
癌症診斷每月營收
癌症診斷每股盈餘
癌症診斷每股淨值
癌症診斷損益表
癌症診斷總資產
癌症診斷負債和股東權益
癌症診斷現金流量表
癌症診斷利潤比率
癌症診斷營業費用率拆解
癌症診斷杜邦分析
癌症診斷ROE / ROA
癌症診斷經營週轉能力
癌症診斷營運週轉天數
癌症診斷現金股利發放率
癌症診斷財務結構比率
癌症診斷流速動比率
癌症診斷利息保障倍數
癌症診斷現金流量分析
癌症診斷營業現金流對淨利比
癌症診斷盈餘再投資比率
癌症診斷月營收成長率
癌症診斷營收成長率
癌症診斷毛利成長率
癌症診斷營業利益成長率
癌症診斷稅後淨利成長率
癌症診斷每股盈餘成長率
癌症診斷本益比評價
癌症診斷股價淨值比評價
癌症診斷現金股利殖利率
癌症診斷平均現金股息殖利率
癌症診斷董監持股比例
癌症診斷董監持股質押比例